MUC16 and ovarian cancer: It is possible to consider applying CA19-9, CA125, NLR, PLR, BDNF and their CV to the screening of patients with inter medium-risk ovarian cancer in the future, which may guide the monitoring of ovarian cancer recurrence and guide patients to timely referral to gynecological oncologists for comprehensive evaluate.